NEW HAVEN, CT, United States
NEW HAVEN, CT, United States

Time filter

Source Type

Patent
Janssen Pharmaceutical and Achillion Pharmaceuticals, Inc. | Date: 2016-09-29

A composition, including a fixed dose composition, comprising Compound (I), Compound (II), and Compound (III) for the treatment of hepatitis C, and methods of manufacture thereof.


Patent
Achillion Pharmaceuticals, Inc. | Date: 2016-08-25

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.


Patent
Achillion Pharmaceuticals, Inc. | Date: 2016-08-25

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R^(12 )or R^(13 )on the A group is an aryl, heteroaryl or heterocycle (R^(32)) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.


Patent
Achillion Pharmaceuticals, Inc. | Date: 2016-08-24

Provided is a compound having a structure selected from the group consisting of:N,N-[tricyclo[8.2.2.24,7]hexadeca-4,6,10,12,13,15-hexaene-5,11-diyl bis [1H-benzimidazole-6,2-diyl[(2S,3aS,7aS)-octahydro-1H-indole-2,1-diyl][(1S)-1-(1-methylethyl)-2-oxo-2,1-ethane diyl]]] bis-, C,C-dimethyl ester, which is a Hepatitis C virus NS5a (HCV NS5a) protease replication inhibitor


Patent
Achillion Pharmaceuticals, Inc. | Date: 2016-08-24

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement.


Patent
Achillion Pharmaceuticals, Inc. | Date: 2016-08-24

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R^(12 )or R^(13 )on the A group is an amide substituent (R^(32)) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade in the alternative complement pathway. The inhibitors of factor D described herein reduce the excessive activation of complement.


Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R^(12 )or R^(13 )on the A group is an aryl, heteroaryl or heterocycle (R^(32)) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce the excessive activation of complement.


Patent
Achillion Pharmaceuticals, Inc. | Date: 2016-08-24

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R^(12 )or R^(13 )on the A group is a phosphonate (R^(32)) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement.


Patent
Achillion Pharmaceuticals, Inc. | Date: 2016-08-24

Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R^(12 )or R^(13 )on the A group is an ether (R^(32)) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement.


The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group P-A-P where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

Loading Achillion Pharmaceuticals, Inc. collaborators
Loading Achillion Pharmaceuticals, Inc. collaborators